India Pharmaceutical & Healthcare provides an overview of the industry in Asia Pacific and India. India’s pharmaceutical industry grew by 9.7% year-on-year in 2009-2010, largely due to robust growth in the domestic market. India’s healthcare industry is expected to grow 14% per year to reach USD 280 billion by 2020. Exports of drugs, pharmaceuticals and fine chemicals accounted for approximately 4.20% of the total national exports in 2010-2011. The report includes the market trends and outlook for the pharmaceutical and healthcare industries in India. We examine the country’s generic production, healthcare equipments, government schemes, TRIPS Compatibility, R&D initiatives, Pharmaceutical Export Promotion Council and India’s Vision 2015. Also, the report encompasses the profile of leading players in the industry as well as their financial highlights and SWOT analysis. Among the leading players are Ranbaxy, Dr Reddy’s, Cipla and Lupin. Ranbaxy is India’s largest pharmaceutical company with operations in 23 of the top 25 pharmaceutical markets of the world. Key Points: • India’s pharmaceutical industry grew by 9.7% year-on-year in 2009-2010, largely due to robust growth in the domestic market. • India’s healthcare industry is expected to grow 14% per year to reach USD 280 billion by 2020. • According to government statistics, exports of drugs, pharmaceuticals and fine chemicals throughout 2010-2011 stood at INR 47,551 cr after a robust growth of 12.0% over 2009-2010.